Gene

ABL1

ABL proto-oncogene 1, non-receptor tyrosine kinase

Explore in graph →CI-GENE-00000153HGNC:76 ENSG00000097007 NCBI 25 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (617)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 351–400 of 617 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 L248V + ABL1 Fusion1
Imatinib Mesylate + NilotinibCombination	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D

Cohorts

Alteration frequency by cohort (122)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved122 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Adenocarcinoma (MSK, J Thorac Oncol 2020) luad_mskcc_2020	Lung Adenocarcinoma	Ssm	13

Literature

Linked publications (65)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 65 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
· Oncotarget · 2017 · PMID 27894077 · validated civic_curation pubmed

ABL1 L364I + ABL1 Fusion3
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	3	accepted	EID4434 Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the L364I secondary variant in 9/12 bacterial clones generated … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	2	submitted	EID4485 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	1	accepted	EID7826 One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later showed the BCR-ABL1 fusion with the L364I secondary varia… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic

ABL1 L364I + ABL1 Fusion3

Dasatinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Does Not Support Resistance

accepted

EID4434

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the L364I secondary variant in 9/12 bacterial clones generated … (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

ABL1 L384M + ABL1 Fusion6
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID4525 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4526 In an in vitro study, a Ba/F3 murine cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with increased sensitivity to bosutinib treatment (… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	1	accepted	EID4527 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4528 In an in vitro study, Ba/F3 cell line stably expressing the L384M mutation in the ABL1 portion of the BCR-ABL fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 4.04 … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Resistance	2	submitted	EID7824 One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the F486S secondary variant in 2/11 clones had partial best cytogenetic response to imatinib before becoming complete… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Imatinib Mesylate + NilotinibSubstitutes	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	1	accepted	EID2861 In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in th… (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic